Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin

Phase 2 Completed 285 enrolled Bristol-Myers Squibb

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to identify one or more doses of BMS-650032 that, when used in combination with pegylated-interferon alpha and ribavirin are safe and demonstrate sufficient activity against hepatitis C virus (Genotypes 1 and 4).

Timeline

Start: 2010-02
Primary completion: 2012-10
Completion: 2012-10

Publications

Bronowicki JP, Ratziu V, Gadano A, Thuluvath PJ, Bessone F, Martorell CT, Pol S, Terg R, Younes Z, He B, Eley T, Cohen D, Yu F, Hernandez D, McPhee F, Mendez P, Hughes E. Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. J Hepatol. 2014 Dec;61(6):1220-7. doi: 10.1016/j.jhep.2014.07.011. Epub 2014 Jul 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Asunaprevir	Small molecule	200 mg	Oral
Background	Peginterferon alfa-2a	Protein / enzyme biologic	180 ug	Subcutaneous
Background	Ribavirin	Small molecule	500 mg	Oral
Background	Ribavirin	Small molecule	600 mg	Oral

Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin

Summary

Timeline

Publications

Drugs

Indications